PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24080403-5 2013 MAO-B inhibitor pargyline (15mg/kg) was systemically administered before neurotoxin administration. Pargyline 16-25 monoamine oxidase B Rattus norvegicus 0-5 25936509-7 2015 The irreversible MAO-B inhibitor Pargyline (65 mg/kg) failed to accumulate N(tau)-MHA in the hypothalamus. Pargyline 33-42 monoamine oxidase B Rattus norvegicus 17-22 17912044-3 2007 This study examined the effects of three MAOIs (phenelzine, clorgyline and pargyline) with varying selectivity for MAOA and MAOB in the nicotine drug discrimination procedure in rats. Pargyline 75-84 monoamine oxidase B Rattus norvegicus 124-128 21341713-5 2011 In intact yeast mitochondria, recombinant rat MAO B is inhibited by the pargyline analogue whereas MAO A activity shows no inhibition. Pargyline 72-81 monoamine oxidase B Rattus norvegicus 46-51 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase B Rattus norvegicus 85-90 15351283-5 2004 As expected, the brain level of PEA escalated to about 6-fold, while the 5-HIAA level remained unchanged following a dose of the MAO B inhibitor pargyline at 2mg/kg. Pargyline 145-154 monoamine oxidase B Rattus norvegicus 129-134 10567696-7 1999 The reduction by MPTP but not MPDP(+) was completely prevented by pargyline, a type B monoamine oxidase (MAO-B) inhibitor, in the synaptosomes. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 105-110 9771127-1 1998 The active immunization of albino rats against pargyline (a MAO B inhibitor) induced the formation of antibody to pargyline and results in deep depressive changes and fear. Pargyline 47-56 monoamine oxidase B Rattus norvegicus 60-65 9813295-7 1998 Systemic monoamine oxidase-B inhibitor pargyline delayed the peak and return to baseline of endogenously produced MPP+ in the nucleus accumbens. Pargyline 39-48 monoamine oxidase B Rattus norvegicus 9-28 9771127-1 1998 The active immunization of albino rats against pargyline (a MAO B inhibitor) induced the formation of antibody to pargyline and results in deep depressive changes and fear. Pargyline 114-123 monoamine oxidase B Rattus norvegicus 60-65 8535333-3 1995 We have developed an iodinated derivative of pargyline, a selective inhibitor of MAO B, in order to explore this enzyme by SPECT. Pargyline 45-54 monoamine oxidase B Rattus norvegicus 81-86 8535333-9 1995 2-iodopargyline has a higher in vitro affinity for MAO B than pargyline. Pargyline 6-15 monoamine oxidase B Rattus norvegicus 51-56 8535333-10 1995 However, the in vitro selectivity for MAO B was better for pargyline than for 2-iodopargyline. Pargyline 59-68 monoamine oxidase B Rattus norvegicus 38-43 11224327-5 1995 Chronic administration (two injections/day for 8 weeks) with a non-selective (i.e. MAO-A and MAO-B inhibiting) dose of pargyline (15mg/kg) resulted in a time-dependent increase in punished responding. Pargyline 119-128 monoamine oxidase B Rattus norvegicus 93-98 11224327-6 1995 In contrast, chronic administration of the MAO-A selective inhibitor (clorgyline; 1.0mg/kg, 2mg/kg), the MAO-B selective inhibitor deprenyl (5mg/kg) or MAO-B inhibiting doses of pargyline (1.0mg/kg, 5mg/kg) were without effect. Pargyline 178-187 monoamine oxidase B Rattus norvegicus 152-157 7931249-7 1994 At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Pargyline 69-78 monoamine oxidase B Rattus norvegicus 107-112 7829993-2 1994 Normal rats treated with clorgyline (a selective MAO-A inhibitor) or tranylcypromine (a non-selective MAO inhibitor) showed a significantly diminished thyroid MAO activity, while deprenyl and pargyline (MAO-B inhibitors) did not modify the thyroidal enzyme activity with respect to the control group. Pargyline 192-201 monoamine oxidase B Rattus norvegicus 203-208 7931249-8 1994 Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Pargyline 86-95 monoamine oxidase B Rattus norvegicus 160-165 2153070-1 1990 Inhibition of monoamine oxidase B (MAO B) by selective inhibitors pargyline and L-deprenyl increases dopamine (DA) and norepinephrine (NE) concentrations in nucleus accumbens (NACB) and is associated with reduction in cold water restraint-induced gastric mucosal injury, inhibition of basal gastric acid output, and regional gastric mucosal blood flow. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 14-33 1431909-2 1992 Irreversible MAO B inhibitors [(-)-deprenyl, pargyline, and MDL 72,974A] stimulated AADC gene expression, whereas a selective irreversible MAO A inhibitor (clorgyline) and a reversible MAO B inhibitor (Ro 19-6327) had no effect. Pargyline 45-54 monoamine oxidase B Rattus norvegicus 13-18 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. Pargyline 24-33 monoamine oxidase B Rattus norvegicus 88-93 1665214-2 1991 Pretreatment with the monoamine oxidase B inhibitor pargyline largely eliminated the perikaryal radiolabeling in the substantia nigra, dorsal raphe and cerebellum, leaving that in the other regions intact. Pargyline 52-61 monoamine oxidase B Rattus norvegicus 22-41 2298362-8 1990 MAO-B inhibitors (pargyline [55%], deprenyl [43%]) but not MAO-A inhibitors (clorgyline [91%]) significantly decreased the frequency of duodenal ulcers suggesting that, like MPTP-induced parkinsonism, formation of a toxic metabolite, probably 1-methyl-4-phenyl-pyridinium is involved. Pargyline 18-27 monoamine oxidase B Rattus norvegicus 0-5 2153070-1 1990 Inhibition of monoamine oxidase B (MAO B) by selective inhibitors pargyline and L-deprenyl increases dopamine (DA) and norepinephrine (NE) concentrations in nucleus accumbens (NACB) and is associated with reduction in cold water restraint-induced gastric mucosal injury, inhibition of basal gastric acid output, and regional gastric mucosal blood flow. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 35-40 3102694-4 1987 Monoamine oxidase B inhibitors (e.g., pargyline, MDL 72145) relieve the inhibition caused by MPTP but not MPP+. Pargyline 38-47 monoamine oxidase B Rattus norvegicus 0-19 2309157-6 1990 Pretreatment with the MAO-B inhibitor pargyline afforded a selective and complete protection of striatal dopamine levels without significantly affecting MPTP-induced striatal serotonin depletions. Pargyline 38-47 monoamine oxidase B Rattus norvegicus 22-27 6527139-6 1984 In contrast, the preferential inhibitors of MAO B, deprenil, pargyline and MD 780236, as well as the nonselective agent tranylcypromine, caused strong (up to about 60-fold) increases. Pargyline 61-70 monoamine oxidase B Rattus norvegicus 44-49 3990515-5 1985 In contrast, the inhibitory effect of PEA on the LC neurons was strongly potentiated by pretreatment with the selective monoamine oxidase (MAO) - B inhibitor pargyline (2 mg/kg, i.p., 1 h), but, unexpectedly, also by pretreatment with the MAO-A selective inhibitors clorgyline (2 mg/kg, i.p., 1 h) or FLA 336 (2 mg/kg, i.p., 1 h). Pargyline 158-167 monoamine oxidase B Rattus norvegicus 120-147 3103805-0 1987 N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl. Pargyline 46-55 monoamine oxidase B Rattus norvegicus 82-106 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase B Rattus norvegicus 298-303 6542783-5 1984 These results show that amitriptyline and pargyline are relatively selective inhibitors of MAO B, whereas pirlindole blocks the A-form of MAO much stronger than MAO B. Pargyline 42-51 monoamine oxidase B Rattus norvegicus 91-96 6817759-5 1982 Pargyline shows a Ki value towards monoamine oxidase B that is only 8 times lower than that towards the A-form and in this case the rates of formation of the enzyme-inhibitor adducts are similar. Pargyline 0-9 monoamine oxidase B Rattus norvegicus 35-54 6622205-3 1983 This makes these compounds more than 10 000 times less potent than the selective MAO-A inhibitor harmaline and more than 10 times less potent than the selective MAO-B inhibitors pargyline and deprenyl. Pargyline 178-187 monoamine oxidase B Rattus norvegicus 161-166 6419132-6 1983 In the case of pargyline, a less selective MAO-B inhibitor, the preference in favour of phenylethylamine was less pronounced. Pargyline 15-24 monoamine oxidase B Rattus norvegicus 43-48 33353806-2 2021 All the compounds exhibited excellent iron-chelating activities (pFe3+ = 14.8-19.2) and showed favorable monoamine oxidase B (MAO-B) inhibitory effects compared to the reference drug Pargyline (IC50 = 86.9 nM). Pargyline 183-192 monoamine oxidase B Rattus norvegicus 105-124 33353806-2 2021 All the compounds exhibited excellent iron-chelating activities (pFe3+ = 14.8-19.2) and showed favorable monoamine oxidase B (MAO-B) inhibitory effects compared to the reference drug Pargyline (IC50 = 86.9 nM). Pargyline 183-192 monoamine oxidase B Rattus norvegicus 126-131